Verastem, Inc. (VSTM)

Verastem, Inc. (VSTM) Healthcare & Pipeline Overview

Verastem, Inc. is a development-stage biopharmaceutical company headquartered in Needham, Massachusetts, dedicated to advancing novel oncology treatments. The company focuses on its lead candidate, VS-6766, a dual RAF/MEK clamp, currently undergoing multiple clinical trials for various cancers, including low-grade serous ovarian cancer and non-small cell lung cancer, leveraging strategic partnerships for development.

What Is the Investment Thesis for VSTM?

Verastem, Inc. presents as a development-stage biopharmaceutical entity with a focused pipeline in oncology, centered on its lead candidate, VS-6766. The investment thesis hinges on the successful progression and eventual commercialization of VS-6766, a dual RAF/MEK clamp, through its ongoing clinical trials. The company's strategic partnerships with Chugai, Pfizer, and Amgen provide significant validation and resources, potentially accelerating development and expanding market opportunities for VS-6766 across indications like low-grade serous ovarian cancer (RAMP 201), KRAS and BRAF mutant non-small cell lung cancer (RAMP 202), and in combination with KRAS-G12C inhibitors (RAMP 203). With a market capitalization of $319.88M and a beta of 0.34, the company's valuation reflects its early-stage nature and inherent clinical development risks. The current negative profit margin of -391.2% is typical for a biopharmaceutical company prior to product commercialization, while a gross margin of 83.7% suggests strong potential profitability if development milestones are met and regulatory approvals are secured. Future clinical trial readouts and potential regulatory submissions represent critical value inflection points. The company's ability to navigate complex clinical development pathways and leverage its intellectual property and collaborative agreements will be key drivers of long-term value creation.

Based on FMP financials and quantitative analysis

VSTM Key Highlights

• Market capitalization stands at $0.30 billion, reflecting its status as a development-stage biopharmaceutical company.
• Reported a gross margin of 83.7%, indicating strong potential profitability on future product sales if commercialized.
• Operating with a profit margin of -391.2%, which is characteristic of a company heavily investing in research and development prior to product launch.
• Exhibits a Beta of 0.34, suggesting lower volatility relative to the broader market, potentially appealing to investors seeking less market-correlated exposure in the biotech sector.
• Focused on a single lead product candidate, VS-6766, currently in multiple clinical trials, representing a concentrated development strategy.

Who Are VSTM's Competitors?

VSTM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VSTM's Key Strengths?

• Focused pipeline with a lead candidate, VS-6766, targeting specific cancer pathways (RAF/MEK).
• Strategic collaborations with major pharmaceutical companies (Chugai, Pfizer, Amgen) validate its science and provide resources.
• Ongoing clinical trials (RAMP 201, RAMP 202, RAMP 203) addressing significant unmet medical needs in oncology.
• High gross margin of 83.7% suggests strong potential profitability post-commercialization.

What Are VSTM's Weaknesses?

• Development-stage company with no commercialized products, leading to a negative profit margin of -391.2%.
• High reliance on the success of a single lead product candidate, VS-6766, and its ongoing clinical trials.
• Significant capital requirements for research and development inherent in the biopharmaceutical industry.
• Limited employee base of 78, potentially indicating resource constraints compared to larger competitors.

What Could Drive VSTM Stock Higher?

• Progress and data readouts from the RAMP 201 trial evaluating VS-6766 for recurrent low-grade serous ovarian cancer, which could provide key insights into efficacy and safety profiles.
• Advancement and interim results from the RAMP 202 Phase 2 trial for VS-6766 in KRAS and BRAF mutant non-small cell lung cancer, signaling progress towards potential regulatory pathways.
• Development updates and preliminary data from the RAMP 203 Phase 1/2 trial, assessing the combination of VS-6766 with Amgen's LUMAKRAS™, which could demonstrate synergistic effects.
• Potential initiation of new clinical trials or expansion into additional indications for VS-6766, broadening the drug's addressable market and therapeutic scope.
• Achievement of significant development or commercialization milestones under existing license agreements with Chugai Pharmaceutical and Pfizer, potentially triggering payments or increased collaboration.

What Are the Key Risks for VSTM?

• Financial-distress signal — its Altman Z-Score of -7.96 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays across any of the RAMP programs (201, 202, 203) could significantly impede product development and future commercialization prospects.
• Regulatory approval risks, including the possibility that VS-6766 may not meet the stringent efficacy and safety standards required by health authorities for market authorization.
• Intense competition within the oncology market from established pharmaceutical companies and other biotechnology firms developing similar or novel cancer treatments.
• Financial sustainability challenges for a development-stage company with a negative profit margin, necessitating ongoing capital raises that could lead to shareholder dilution.
• Intellectual property challenges, including patent disputes or the inability to maintain exclusive rights to its drug candidates, which could undermine future revenue potential.

What Are the Growth Opportunities for VSTM?

• **Advancement in Low-Grade Serous Ovarian Cancer (RAMP 201):** The RAMP 201 trial, evaluating VS-6766 alone and in combination with defactinib for recurrent low-grade serous ovarian cancer, represents a significant growth opportunity. This specific cancer type often has limited effective treatment options, indicating a high unmet medical need. Successful clinical outcomes and subsequent regulatory approval could position VS-6766 as a critical therapy in this niche, potentially capturing a substantial share of this specialized market. The progress of this adaptive two-part multicenter trial is a key determinant of future revenue streams and market penetration, with potential timelines for data readouts influencing market perception and valuation.
• **Expansion into KRAS and BRAF Mutant NSCLC (RAMP 202):** The ongoing Phase 2 RAMP 202 trial, investigating VS-6766 with defactinib for KRAS and BRAF mutant non-small cell lung cancer (NSCLC) post-platinum-based regimen and immune checkpoint inhibitor treatment, targets a large and evolving oncology market. NSCLC, particularly with these mutations, remains a challenging disease with a need for more effective second-line and beyond therapies. Positive results from RAMP 202 could unlock a significant patient population, offering a new treatment paradigm and substantially increasing Verastem's addressable market. The success here would validate the broad applicability of VS-6766 beyond ovarian cancer.
• **Synergistic Combination with Amgen's LUMAKRAS (RAMP 203):** The clinical collaboration with Amgen, evaluating VS-6766 in combination with LUMAKRAS™ (a KRAS-G12C inhibitor) in the Phase 1/2 RAMP 203 trial, offers a compelling growth avenue. Combining therapies that target different pathways can lead to enhanced efficacy and overcome resistance mechanisms. If this combination proves superior to monotherapy, it could establish a new standard of care for KRAS-G12C mutant cancers, a segment with high commercial potential. This partnership leverages Amgen's established market presence and Verastem's innovative mechanism, potentially accelerating market access and adoption for VS-6766.
• **Leveraging Strategic Licensing and Development Partnerships:** Verastem's license agreements with Chugai Pharmaceutical Co., Ltd. for VS-6766 and Pfizer Inc. for FAK inhibitors are crucial for long-term growth. These partnerships provide access to significant resources, expertise, and potentially broader geographic reach for development, manufacturing, and commercialization. Such collaborations can de-risk development, share costs, and accelerate the path to market. The success of these alliances in advancing pipeline candidates and exploring new indications or formulations could significantly enhance Verastem's value proposition and future revenue streams over the next several years.
• **Broadening Therapeutic Applications and Pipeline Diversification:** While currently focused on VS-6766, the underlying scientific platform and expertise in RAF/MEK and FAK inhibition could enable Verastem to explore additional therapeutic applications or develop new compounds. Identifying and pursuing new indications for VS-6766 or initiating research into novel targets within oncology or related therapeutic areas represents a long-term growth opportunity. This diversification could mitigate reliance on a single drug candidate and expand the company's overall market potential, potentially attracting further investment and partnerships in the coming decade as new targets are validated.

What Opportunities Does VSTM Have?

• Successful clinical trial outcomes for VS-6766 could lead to regulatory approvals and market entry in high-value oncology segments.
• Expansion of VS-6766's indications beyond current trials, potentially addressing a broader range of cancers.
• Further strategic partnerships or licensing deals could provide additional funding, expertise, and market access.
• Advancements in precision oncology and biomarker identification could enhance the targeted application and efficacy of VS-6766.

What Threats Does VSTM Face?

• Clinical trial failures, delays, or unexpected safety issues could significantly impact the company's prospects.
• Intense competition from other pharmaceutical companies developing similar or alternative cancer therapies.
• Regulatory hurdles and the lengthy, costly drug approval process pose inherent risks.
• Dependence on external funding and potential dilution of shareholder value through future equity offerings to finance operations.

What Are VSTM's Competitive Advantages?

• Proprietary drug candidate VS-6766 with a unique dual RAF/MEK clamp mechanism, offering a differentiated approach to cancer treatment.
• Intellectual property protection surrounding VS-6766 and its applications in various oncology indications.
• Strategic licensing and clinical collaboration agreements with established pharmaceutical companies like Chugai, Pfizer, and Amgen, providing validation and resources.
• Specialized focus on specific, high-unmet-need cancer types, allowing for concentrated development efforts and potential market leadership in niche areas.

What Does VSTM Do?

Verastem, Inc., incorporated in 2010 and headquartered in Needham, Massachusetts, operates as a development-stage biopharmaceutical company singularly focused on the discovery, development, and potential commercialization of innovative drugs for the treatment of cancer. The company's strategic approach centers on addressing significant unmet medical needs within oncology through targeted therapies. At the core of its pipeline is VS-6766, a proprietary dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp. This investigational compound is designed to block MEK kinase activity and inhibit the ability of RAF to phosphorylate MEK, thereby disrupting critical signaling pathways involved in cancer cell growth and survival. Verastem's clinical development efforts for VS-6766 are extensive, encompassing several pivotal trials. These include RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open-label trial evaluating the efficacy and safety of VS-6766, both as a monotherapy and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK), for patients with recurrent low-grade serous ovarian cancer. Additionally, the company is advancing RAMP 202, a Phase 2 trial assessing the safety and efficacy of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer who have previously undergone treatment with a platinum-based regimen and an immune checkpoint inhibitor. Verastem has also established key strategic alliances to bolster its development capabilities and potential market reach. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766. Furthermore, a collaboration with Pfizer Inc. grants Verastem rights to research, develop, manufacture, and commercialize products containing Pfizer's FAK inhibitors for therapeutic, diagnostic, and prophylactic uses in humans. A significant clinical collaboration agreement with Amgen, Inc. is also in place to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM in a Phase 1/2 trial designated as RAMP 203. These partnerships are integral to Verastem's strategy, enabling the exploration of VS-6766's potential across a broader spectrum of cancer types and treatment paradigms.

What Products and Services Does VSTM Offer?

• Develops and commercializes drugs for the treatment of cancer.
• Focuses on its lead product candidate, VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp.
• Conducts RAMP 201, an adaptive two-part clinical trial for recurrent low-grade serous ovarian cancer, evaluating VS-6766 alone and with defactinib.
• Manages RAMP 202, a Phase 2 trial for KRAS and BRAF mutant non-small cell lung cancer, testing VS-6766 in combination with defactinib.
• Collaborates with Amgen, Inc. on RAMP 203, a Phase 1/2 trial combining VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRAS™.
• Holds license agreements with Chugai Pharmaceutical Co., Ltd. for VS-6766 development and commercialization.
• Has an agreement with Pfizer Inc. for research, development, manufacture, and commercialization of Pfizer's FAK inhibitors.

How Does VSTM Make Money?

• Focuses on research and development of novel oncology drug candidates, primarily VS-6766, through various clinical trial phases.
• Generates potential future revenue through the commercialization of approved drugs, or through licensing agreements and milestone payments from strategic partners.
• Engages in strategic collaborations with larger pharmaceutical companies to share development costs, leverage expertise, and expand market access for its investigational therapies.
• Aims to address unmet medical needs in specific cancer types by developing targeted therapies that interfere with critical cancer signaling pathways.

What Industry Does VSTM Operate In?

Verastem, Inc. operates within the highly specialized and competitive biotechnology industry, specifically targeting the oncology therapeutic area. The global oncology market is characterized by significant unmet medical needs and continuous innovation, driven by advancements in molecular biology and precision medicine. This market is projected to experience substantial growth, fueled by an aging global population, increasing cancer incidence, and the development of novel targeted therapies. Verastem's focus on VS-6766, a dual RAF/MEK clamp, positions it within the segment of targeted cancer therapies, which aim to interfere with specific molecular pathways involved in tumor growth. The competitive landscape includes numerous established pharmaceutical giants and emerging biotech firms developing similar or alternative oncology treatments. Success in this industry is heavily reliant on robust clinical data, regulatory approvals, and effective commercialization strategies. Verastem's strategy of developing VS-6766 for specific indications like low-grade serous ovarian cancer and KRAS/BRAF mutant non-small cell lung cancer, coupled with strategic collaborations, aims to carve out a niche within this dynamic and high-stakes market.

Who Are VSTM's Key Customers?

• Ultimately, patients suffering from various cancer types, including low-grade serous ovarian cancer and KRAS/BRAF mutant non-small cell lung cancer.
• Oncologists and healthcare providers who prescribe and administer cancer treatments.
• Strategic pharmaceutical partners (e.g., Chugai, Pfizer, Amgen) who collaborate on development, manufacturing, and potential commercialization.
• Regulatory bodies that approve new drug therapies for market entry.

Company Profile

Verastem, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Needham, US. The company is led by CEO Daniel W. Paterson. VSTM has traded publicly since 2012.

How Verastem, Inc. Is Valued

Verastem, Inc. carries a market capitalization of $319.88M, placing it in the small-cap category. Relative to its peer group, VSTM's quantitative score of 11/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -85.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -53.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -48.1%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

Verastem, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -7.96 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Verastem, Inc. revenue of about $102.3M for fiscal 2026, with EPS near $-1.56. The estimate reflects 7 contributing analysts.

Net buyingInsider Activity

Over the past six months, Verastem, Inc. insiders filed 15 SEC Form 4 transactions — 4 sales and 11 purchases. On net that is roughly 573K shares acquired (about $121K) — insiders putting money in tends to read as conviction.

VSTM Financials

VSTM Latest News

VSTM Analyst Consensus

VSTM MoonshotScore

VSTM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources